权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Abnormal Extracellular Vesicles and Particles from Human Islets Impact T1D progression

来自人类胰岛的异常细胞外囊泡和颗粒影响 T1D 进展

基本信息

批准号：
10754074
负责人：
Shuibing Chen
金额：
$ 72.91万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-21 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10754074
关键词：
Alpha Cell Antigen Presentation Antigen-Presenting Cells Apoptotic Beta Cell Binding Biological Markers Biology Blood Vessels Body Fluids Cell Communication Cell Line Cell Survival Cell membrane Cell physiology Cells Coxsackie Viruses DNA Databases Development Diagnosis Endocrine Endothelial Cells Field Flow Fractionation Functional disorder Heterogeneity Human Immune Insulin-Dependent Diabetes Mellitus Islet Cell Lipid Bilayers Lipids MLLT2 gene Macrophage Mediating Mediator Membrane Membrane Proteins Methods MicroRNAs Microfluidic Microchips Molecular Molecular Profiling Organ Organoids Outcome Pancreas Pathogenicity Pathologic Patient Care Patients Plasma Proteins Proteomics RNA Role Sampling Slice Stress Structure Technology Testing Tissues Ultracentrifugation Vascular blood supply Vascularization autoreactivity cell type cytokine diabetes pathogenesis exosome extracellular extracellular vesicles gain of function human pluripotent stem cell insulin dependent diabetes mellitus onset islet mouse model nanoparticle novel marker novel therapeutic intervention novel therapeutics particle prevent senescence signature molecule superresolution imaging

项目摘要

Abstract. Extracellular vesicles and particles (EVPs) are a group of heterogeneous nanoparticles that are secreted into the extracellular milieu by many types of cells. EVPs have emerged as important mediators in cell-to-cell communications within organs. Recent studies have suggested that EVPs might be involved in β cell-immune cell interaction and β cell dysfunction and survival in type 1 diabetes (T1D). However, many of these studies were performed using mouse models and not focused on human samples. Hence, there is a unmet need to understand the contribution of human islet/pancreas-associated EVPs in T1D progression. Here, we have assembled an interdisciplinary team, including experts in islet biology (Chen, Liu), EVP biology (Lyden), vascular biology (Rafii), and T1D patient care (Antal), to test the hypothesis that abnormal EVPs of pathogenic human islets and pancreatic tissues disrupt human islet function and survival and trigger T1D progression. We have performed extensive proteomics analyses of EVPs derived from human β cell lines cultured in T1D conditions. In addition, by comparing the plasma membrane protein profiles of human β cell line and primary human islet-derived EVPs with an EVP proteomic database containing 426 human samples, we have identified several plasma membrane protein candidates to isolate β cell-specific EVPs. Here, we will use multiple platforms, including primary human islets from healthy, pre-T1D, and T1D donors, human pluripotent stem cell (hPSC)-derived islet organoids, perfusable microfluidic devices containing vascularized islets, and pancreatic slice culture to systematically examine the role of human islet/pancreas-associated EVPs in islet cell function and survival during T1D progression. In this proposal, we expect to identify membrane-bound EVP protein panels to purify EVPs from human α, β cells, islets, and pancreatic tissue. We will define the EVP protein and RNA profiles and identify signature molecules associated with islet status during T1D progression. Moreover, we will systemically dissect the roles of human islet/pancreas EVPs in human β cell function and survival, as well as their role in the crosstalk between β cells and peri-islet cell niche. Overall, this study will facilitate the identification of novel “biomarkers” for T1D diagnosis and guide the development of new therapeutic strategies to treat and prevent the progression of T1D.

摘要。